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Abstract
Background: Using new molecular biology techniques, recent studies have implicated a common evolutionary
pathway between lobular neoplasia, lobular carcinomas, and columnar cell lesions. Our aims were to assess the
frequency of lobular neoplasia in a series of breast biopsies that were performed and examined in the same
institution and to analyze the association between subtypes of lobular neoplasia and benign and malignant breast
lesions.
Methods: Cases were selected after reviewing archived pathological reports in the Breast Pathology Laboratory,
School of Medicine of Federal University of Minas Gerais (1999-2008). Cases of lobular neoplasia were reviewed and
classified as atypical lobular hyperplasia, ductal involvement by cells of atypical lobular hyperplasia, lobular
carcinoma in situ, and pleomorphic lobular carcinoma in situ. Coexistence of lobular neoplasia with other breast
lesions, including columnar cell lesions, invasive ductal carcinoma and invasive lobular carcinoma, was evaluated.
The association between lobular neoplasia and breast lesions was analyzed by Fisher’s exact test and chi-square
test for linear trend.
Results: We analyzed 5650 breast specimens, selecting 135 breast specimens (2.4%) that had a diagnosis of lobular
neoplasia, corresponding to 106 patients. Hematoxylin and eosin-stained slides were available for 84 cases, 5 of
which were excluded because they contained only “indeterminate” in situ lesions. Of the 79 remaining cases,
columnar cell lesions were present in 78.5%, primarily with columnar cell changes without atypia (67.7%). Invasive
carcinoma was present in 45.6% of cases of lobular neoplasia–a similar frequency (47.2%) as invasive ductal
carcinoma and invasive lobular carcinoma. We noted a significant linear trend (p < 0.03) of a higher frequency of
invasive carcinomas that were concomitant with lobular carcinoma in situ compared with atypical lobular
hyperplasia. Invasive lobular carcinomas were associated with lobular carcinoma in situ in 33% of cases, compared
with 2.8% of atypical lobular hyperplasia cases.
Conclusions: Our findings confirm a frequent association between lobular neoplasia and columnar cell lesions, the
majority of which lacked atypia. We also observed a greater frequency of invasive carcinoma, more commonly
invasive lobular carcinoma, associated with more developed forms of lobular neoplasia (lobular carcinoma in situ).
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Background
Lobular carcinoma in situ (LCIS) was first described by
Foote and Stewart in 1941, designated as such due to its
cytological similarities with invasive lobular carcinoma
(ILC): cuboidal and regular and harboring discohesive
cells, often containing cytoplasmic vacuoles. LCIS was
originally considered a precursor of invasive carcinoma
due to its frequent association with invasive lobular car-
cinoma [1]. Subsequent epidemiological studies demon-
strated that the risk of developing invasive lesions was
not as high as expected, progressing slowly and forming
in the ipsilateral and contralateral breast [2].
Other studies confirmed the indolent nature of LCIS;
clinically, LCIS was considered a risk marker for inva-
sive breast cancer. The consequent risk was proportional
to the extent of disease and was evaluated, based on
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affected by neoplastic cells [3,4]. Due to its indolent
behavior, Haagensen et al. proposed replacing the term
“lobular carcinoma” with “lobular neoplasia” to decrease
the impact of the malignancy and the link to mortality
that is associated with the term “carcinoma” [2].
Page et al. correlated the extension of lobular involve-
ment and the risk of breast cancer, proposing a semi-
quantitative stratification method–designating lobular
lesions in atypical lobular hyperplasia (ALH) for less
extensive lesions and LCIS for more extensive lesions. A
4- to 5-fold relative risk of developing invasive carci-
noma was observed for ALH lesions, whereas for CLIS,
the relative risk was 8 to 11 times greater than the gen-
eral population [4]. The ductal involvement by cells of
atypical lobular hyperplasia (DIALH), also called page-
toid spread, carried an intermediate risk of developing
carcinoma of 6.8-fold [5].
Although Page’s classification has been used widely
over the past 20 years, the latest World Health Organi-
zation (WHO) classification of tumors groups these
lesions under lobular neoplasia (LN), without consider-
ing their development [6].
Recent molecular biology studies have revealed more
about lobular neoplasia. Genetic similarities, such as the
loss of chromosomal material on 16q and gains on 1q,
have been observed in LN and other low-nuclear grade
breast lesions. Similar genetic alterations were detected
in columnar cell lesions (CCLs), low-grade ductal carci-
noma in situ (DCIS), tubular carcinoma (TC), and ILC.
These similarities suggest a common evolutionary path-
way, in which low-grade precursor lesions progress to
low-grade invasive and in situ carcinomas [7-9].
Columnar cell lesions coexist frequently with DCIS,
and low-grade invasive carcinomas, particularly TC and
ILC [10-13]. However, few studies have evaluated this
association, based on the diagnosis of LN, in routinely
removed breast specimens [14,15].
The aims of this study were to assess the frequency of
LN in a series of breast biopsies that were performed
and examined in the same institution and to analyze the
association between subtypes of LN with benign and
malignant breast lesions.
Methods
We accessed the archives of the Breast Pathology
Laboratory (BPL) of the School of Medicine of Federal
University of Minas Gerais from August 1999 to
December 2008, selecting all breast specimens with
diagnoses of ALH, DIAL, LCIS, and pleomorphic LCIS.
Cases of LN with original hematoxylin and eosin
(H&E)-stained slides were reviewed by DSG and HG
using a double-headed optical light microscope and
included in the study. Breast biopsy specimens from the
same patient were considered one case. Cases with only
core needle biopsy specimens were excluded.
We used the histological criteria per Page et al. to
classify ALH, DIALH, and LCIS [3-5]. LCIS was defined
as complete involvement of the lobules by neoplastic
cells, with greater than 50% of a lobule completely
replaced and distended by neoplastic and monomorphic
cells. ALH was defined as lobules that were partially dis-
tended by neoplastic cells, failing to meet the criteria for
LCIS. DIALH was diagnosed when the ALH cells
extended between the epithelial layer and the basement
membrane of the terminal duct.
T h ec r i t e r i at h a tw eu s e dt od i a g n o s ep l e o m o r p h i c
LCIS was described by Eusebi et al.–the same architec-
tural pattern as LCIS but with larger nucleoli and
nuclear pleomorphism [16]. Cases that harbored more
than one subtype of LN were classified by the lesion
with the greatest risk of developing carcinoma: pleo-
morphic LCIS > Classic LCIS > DIALH > ALH. The
term “indeterminate in situ lesions” (IILs) or “mixed
type lesions” was used to describe certain breast carci-
nomas in situ, in which the cytological or architectural
properties and distribution deviated from the typical
patterns, rendering it difficult, if not impossible, to
determine whether the proliferation was lobular or duc-
tal, based only on morphological criteria [17]. These
cases were not included in our analysis.
The frequency of the association of LN was analyzed
for the following diagnoses: CCL, per Schnitt and Vin-
cent-Salomon [18], who divided the lesions into colum-
nar cell change without atypia (CCC); columnar cell
change with atypia (CCC with atypia); columnar cell
hyperplasia without atypia (CCH); and columnar cell
hyperplasia with atypia (CCH with atypia). The presence
of in situ and invasive carcinoma was noted, as were
their type and histological tumor grade. The tumors
were classified per Page et al. and the American College
of Pathology [19,20]. The Nottingham grading system
was used for histological grading [21].
Statistical analysis was performed using SPSS (version
1 7 . 0 ,S P S SI n c ,C h i c a g o ,I L ,U S A ) .D i f f e r e n c e si nm e a n
age between LN groups was calculated by ANOVA, and
the association between LN and breast lesions was ana-
lyzed using Fisher’se x a c tt e s t ,c
2 test, and c
2 test for
trend. The study was approved by the ethical committee
of the UFMG.
Results
During the study period, 5650 breast specimens from
the same institution were analyzed. From the original
reports, 135 breast specimens (2.4%) were diagnosed
with a subtype of lobular neoplasia, corresponding to
106 patients, 21 of whom had 2 or more consecutive
biopsies. H&E-stained slides were available for 84
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Page 2 of 6patients, slides for 5 of whom were excluded because
they contained only indeterminate in situ lesions. The
frequencies of LN subtypes and the average patient ages
are shown in Table 1. There was no significant differ-
ence in patient age between subgroups of patients with
LN (p = 0.425).
We observed a frequent association of LN with CCL
(62/79 cases, 78.5%) and with most cases of CCC with-
out atypia (42/62 cases, 67.7%). We observed a signifi-
cant linear association (p = 0.03), wherein the frequency
of LN tended to correlate negatively with the degree of
atypical columnar lesions (Table 2). Twenty-three cases
(29.1%) presented with coexisting LN, CCL, and invasive
carcinoma (Table 2). Twenty cases (87%) comprised
CCC or CCH without atypia, and 3 cases (13%) had
CCC or CCH with atypia. There were no significant dif-
ferences in the association of columnar lesions with or
without atypia with regard to histological type and
tumor grade of the invasive carcinomas. The coexistence
of TC, LN, and CCL, reported by some groups as
“Rosen’s triad” [11], was observed in 1 case.
Moderate or usual ductal hyperplasia without atypia
and atypical hyperplasia were present in 40% and 10.1%
of 79 LN cases, respectively, but no significant difference
in the association with LN subtypes was observed.
LN was associated with DCIS in 21.5% of cases, and
high-grade DCIS correlated more often with LN (64.7%
of cases). There were no cases that of concomitant
DCIS and pleomorphic LCIS. Although there was no
significant difference between LN subtypes, LCIS was
most often associated with DCIS (47.1%) (Table 3). We
noted 7 cases (8.9%) of LN and DCIS without concur-
rent invasive carcinoma–5 high-grade, 1 moderate, and
1 low-grade. Invasive carcinomas were present with LN
in 45.6% of cases, with similar rates of association with
invasive ductal carcinomas (IDCs) and ILC (47.2%).
With regard to cases of ILC, however, we observed a
higher frequency of ILC that was associated with LCIS
(33.3%) compared with DIALH (11.1%) and ALH (2.8%)
(Table 4). No significant difference was noted in the link
between histological grade of the invasive carcinoma and
LN subtype in any group (Table 5).
Discussion
The frequency of diagnosis of lobular neoplasia in our
study was 2.4% in a consecutive series of routinely
removed breast specimens in a general hospital. The
rate of LCIS ranges from 0.5% to 3.6% of breast speci-
mens [2,3]. Because there are no obvious clinical or
radiological features, the true incidence of LN in the
general population is unknown [22,23].
Table 1 Frequency of subtypes of lobular neoplasia (LN)
and mean age of patients
LN n % Mean age (years) ± SD
ALH 22 26.2 50.2 ± 9.0
DIALH 25 29.8 50.2 ± 9.7
LCIS 29 34.5 51.3 ± 10.6
LCIS pleo 3 3.6 49.3 ± 8.1
IIL 5 6.0 58.2 ± 8.1
Total 84 100.0 52.0 ± 9.7
ALH = atypical lobular hyperplasia; DIALH = ductal involvement by cells of
atypical lobular hyperplasia; LCIS = lobular carcinoma in situ; LCIS pleo =
pleomorphic LCIS; IIL = indeterminate in situ lesions. There was no difference
in mean age among patients with different lesions (p = 0.425); n = number of
cases; SD = standard deviation.
Table 2 Frequency of association between subtypes of
lobular neoplasia and columnar cell lesions (CCL)
CCL ALH DIALH LCIS LCIS pleo Total
n% n% n% n % n%
CCC 14 22.6 13 21.0 15 24.2 0 0 42 67.7
CCH 4 6.5 3 4.8 2 3.2 0 0 9 14.5
CCC with atypia 1 1.6 3 4.8 4 6.5 1 1.6 9 14.5
CCH with atypia 0 0 0 0.0 1 1.6 1 1.6 2 3.2
Total 19 30.6 19 30.6 22 35.5 2 3.2 62 100.0
ALH = atypical lobular hyperplasia; DIALH = ductal involvement by cells of
atypical lobular hyperplasia; LCIS = lobular carcinoma in situ; LCIS pleo = LCIS
pleomorphic; CCC = columnar cell change; CCH = columnar cell hyperplasia;
CCC with atypia = columnar cell change with atypia; CCH with atypia =
columnar cell hyperplasia with atypia; n = number of cases. c
2 test for trend:
p = 0.03.
Table 3 Association between subtypes of lobular
neoplasia and histological grade of ductal carcinoma in
situ
Histological grades of DCIS ALH DIALH LCIS Total
n% n% N% n %
Low 0 0.0 2 11.8 2 11.8 4 23.5
Intermediate 1 5.9 0 0.0 1 5.9 2 11.8
High 2 11.8 4 23.5 5 29.4 11 64.7
Total 3 17.6 6 35.3 8 47.1 17 100.0
ALH = atypical lobular hyperplasia; DIALH = ductal involvement by cells of
atypical lobular hyperplasia; LCIS = lobular carcinoma in situ; DCIS = ductal
carcinoma in situ. There was no difference between groups.
Table 4 Association subtypes of lobular neoplasia and
histological type of invasive carcinomas
Histological types ALH DIALH LCIS Total
n% n% N % n %
IDC 4 11.1 4 11.1 9 25.0 17 47.2
ILC 1 2.8 4 11.1 12 33.3 17 47.2
Tubular carcinoma 0 0.0 1 2.8 0 0.0 1 2.8
Micropapillary 0 0.0 0 0.0 1 2.8 1 2.8
Total 5 13.9 9 25.0 22 61.1 36 100.0
ALH = atypical lobular hyperplasia; DIALH = ductal involvement by cells of
atypical lobular hyperplasia; LCIS = lobular carcinoma in situ; IDC = invasive
ductal carcinoma; ILC = invasive lobular carcinoma;. c
2 test for trend: p = 0.03.
There was no difference between groups.
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Page 3 of 6The diagnosis of LN is typically related to an inciden-
tal finding on breast biopsies that are performed for
other indications. With the increasing use of mammo-
graphy, lobular neoplasia has been observed in associa-
tion with microcalcifications in up to 40% of cases that
are diagnosed by core needle biopsy [24]. Microcalcifica-
tions rarely form within LNs and they usually correlate
with other benign or malignant breast lesions–the diag-
nosis of LN is most often incidental [23].
Columnar cell lesions (CCLs) comprise a spectrum of
morphological alterations of the duct epithelial lining,
acquiring a columnar cell appearance and involving vari-
ably dilated acini of the terminal duct lobular unit
(TDLU) [25]. There has been recent, increasing interest
in these lesions, because they are detected in up to 42%
of the breast biopsies that are performed due to the pre-
sence of microcalcifications by mammography [26].
For instance, many terms have been used to describe
CCLs, from “b l u n td u c ta d e n o s i s ” to “clinging carci-
noma” [25,27]. Nevertheless, Schnitt and Vincent-Salo-
mon’s nomenclature and diagnostic criteria of CCL have
been the most widely used [18], whereas in the most
recent WHO guidelines, CCL was included under the
term “flat epithelial atypia” (FEA) [6]. After the release
of the WHO classification, Schnitt began referring to
CCC and CCH with atypia as “flat atypia” [28].
CCLs have been linked to lobular neoplasia, low-grade
DCIS, and invasive carcinoma. Further, similar genetic
abnormalities have been found in CCC and CCH with
atypia or FEA and the associated low-grade DCIS and
invasive carcinoma. These findings have led to the rea-
sonable conclusion that CCC and CCH with atypia are
the earliest morphologically identifiable precursor
lesions of low-grade DCIS and invasive carcinoma
[8,15,25].
Yet, there are no prospective randomized trials, and
few epidemiological studies with patients with only CCC
and CCH with atypia have evaluated the prognosis of
these lesions. Several studies, comprising a limited num-
ber of cases, demonstrated little or no risk for
progression to invasive carcinoma [29-32]. Thus, there
remains no consensus on the ideal treatment for these
atypical lesions.
In our series, LN and CCL coexisted in 78.5% of cases,
most often as mild forms of the spectrum of CCL–eg,
CCC without atypia (67.7%). Our data are consistent
with a recent study that examined 68 core needle biopsy
specimens with a diagnosis of LN due to the excision of
microcalcifications. The authors demonstrated an asso-
ciation between LN and CCL in 54% of cases, none of
which presented with CCC or CCH with atypia after
wide excision biopsy [15]. However, after analyzing 111
breast biopsies with LN but no other in situ or invasive
carcinomas, Leibl et al. noted that LN was associated
with FEA–ie, CCC and CCH with atypia in 86.5% of
cases [33]. Our studies and other reports have observed
a frequent association of CCL with LN, but they differ
regarding the presence or absence of atypia.
There are many terms for LCC. Moreover, the WHO
morphological definition of FEA is imprecise and does
not describe the cytological and architectural features
that are necessary for its diagnosis. In our study, all
cases were reviewed by 2 observers, including a well-
trained breast pathologist (HG). We used well-defined
diagnostic criteria per Schnitt and Vincent-Salomon and
noted fewer cases of CCC and CCH with atypia than
what has been reported [10,11,33]. We believe that in
many series and cases in our Breast Consulting Labora-
tory, FEA is being overdiagnosed, which could lead to
the implementation of more aggressive treatments [34].
The frequency of invasive carcinomas that were asso-
ciated with LN in our series was 45.6%, and we observed
a similar frequency of ILC (47.2%) and invasive ductal
carcinoma (IDC). However, when LN subtypes were
analyzed separately, we observed a 4-fold higher fre-
quency of IDC that was associated with ALH versus ILC
and a greater link between ILC (33.3%) and LCIS com-
pared with IDC. We also noted a 12-fold increase in the
correlation between ILC and LCIS (33.3%) compared
with ALH (2.8%).
Our data are consistent with a series of 775 cases of
LN [14]. Bratthauer and Tavassoli stratified the LNs as
“lobular intraepithelial neoplasias” (LINs) and evalu-
ated the frequency of association between LIN sub-
t y p e s( 1 ,2 ,a n d3 )a n di n v a s i v ec a r c i n o m a .T h e
percentage of LIN 1 (equivalent to ALH) that was
associated with invasive carcinoma was 14%, and 89%
of these tumors were IDCs. In the patients with LIN 3
(equivalent to LCIS), the frequency of association with
IDC and ILC was 23% and 86%, respectively. The
authors concluded that the advance from LIN 1 to LIN
3 was linked to a 64% increase in the frequency of
invasive carcinoma and a greater than 700% rise in the
likelihood of ILC [14].
Table 5 Association between subtypes of lobular
neoplasia and histological tumor grade of invasive
carcinomas
Tumor grade ALH DIALH LCIS Total
n% n% n % n %
Low 1 2.8 3 8.3 12 33.3 16 44.4
Intermediate 2 56 4 11.1 9 25.0 15 41.7
High 2 5.6 2 5.6 1 2.8 5 13.9
Total 5 13.9 9 25.0 22 61.1 36 100.0
ALH = atypical lobular hyperplasia; DIALH = ductal involvement by cells of
atypical lobular hyperplasia; LCIS = lobular carcinoma in situ; IDC = invasive
ductal carcinoma; ILC = invasive lobular carcinoma. There was no difference
between groups.
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lobular neoplasia is not only a risk indicator but also a
nonobligate precursor of invasive breast carcinoma [23].
Invasive carcinomas that develop after a diagnosis of
ALH are 3 times more likely to arise in the ipsilateral
rather than contralateral breast [35].
Lobular neoplasia and ILC are detected together fre-
quently in the same specimen and location of the
tumor–in up to 90% of cases of ILC [10]. These lesions
have similar immunohistochemical profiles, including
the loss of expression of E-cadherin and b-catenin and
the cytoplasmic localization of p120-catenin [36]. Inva-
sive and in situ lobular carcinomas confer similar
genetic gains and losses, often bearing the same muta-
tions in the gene that encodes E-cadherin (CDH1)
[7,37,38].
However, it is unknown why LCIS carries a greater
risk of progression to invasive disease and is associated
more frequently with invasive lobular carcinoma com-
pared with ALH. Mastracci et al. demonstrated that
somatic alterations in CDH1 are a hallmark of LCIS but
not ALH [39]. This disparity suggests that mutations
that inactivate CDH1 can distinguish LNs that are able
to progress to invasive disease, explaining our morpho-
logical data [39].
Conclusions
Our findings confirm a frequent association between
lobular neoplasia and CCL without atypia, thereby dif-
fering from other studies in which the majority of CCL
is classified as CCL with atypia or FEA. We also noted a
higher frequency of invasive carcinoma, more commonly
ILC, that was associated with more developed forms of
LN (LCIS).
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